Overview
Jenny is a Consultant Clinical Neuropsychologist and Chartered Clinical Psychologist who has worked in a range of private and NHS settings including services for traumatic brain injury, neuro-oncology and epilepsy surgery. Jenny gained her PhD, in the behaviour and learning of children with intellectual disability, at Southampton University (1992-1998). Following this Jenny completed her Clinical Psychology training at University College London (1997-2000), undertaking her doctoral research on the illness perceptions of children with nephrotic syndrome. As a post-doctoral research fellow (Institute of Child Health, UCL), Jenny investigated different learning paradigms in developmental amnesia. Jenny was the Neuropsychology Chair of The European Society for Paediatric Oncology (SIOP – Europe) Brain Tumour Quality of Survival Group (2012-2017) and continues to be involved in developing quality of survival protocols for clinical trials in Europe. Jenny’s research and clinical interests are in developing interventions for children with neurological conditions, including traumatic brain injury, brain tumours, CNS infections and neurodevelopmental disorders. Areas of particular interest include the impact of development on response to interventions, metacognition and interventions to support executive functioning, processing speed, memory and learning. Jenny also has a strong interest in developing single-case experimental designs to facilitate clinical research.
Jenny is currently a Senior Lecturer and Research Director for the DClinPsy programme at the University of Exeter, and is the Consultant Clinical Neuropsychologist for the Child and Adolescent Neuropsychology (CAN) Clinic, currently being piloted at the University.
Publications
Key publications | Publications by category | Publications by year
Publications by category
Journal articles
Limond J, Thomas S, Bull KS, Calaminus G, Lemiere J, Traunwieser T, van Santen HM, Weiler L, Spoudeas HA, Chevignard M, et al (2020). Quality of survival assessment in European childhood brain tumour trials, for children below the age of 5 years.
Eur J Paediatr Neurol,
25, 59-67.
Abstract:
Quality of survival assessment in European childhood brain tumour trials, for children below the age of 5 years.
The highest incidence rate of childhood brain tumours is in children below the age of five years, who are particularly vulnerable to the effects of treatments. The assessment of quality of survival (QoS) in multiple domains is essential to compare the outcomes for different tumour types and treatment regimens. The aim of this position statement is to present the domains of health and functioning to be assessed in children from birth to five years, to advance the collection of a common QoS data set in European brain tumour trials. The QoS group of the European Society of Paediatric Oncology (SIOP-E) Brain Tumour group conducted consensus discussions over a period of six years to establish domains of QoS that should be prioritised in clinical trials involving children under 5 years. The domains of health and functioning that were agreed to affect QoS included: medical outcomes (e.g. vision, hearing, mobility, endocrine), emotion, behaviour, adaptive behaviour, and cognitive functioning. As for children aged five years and older, a 'core plus' approach is suggested in which core assessments are recommended for all clinical trials. The core component for children from birth to three years includes indirect assessment which, in this age-group, requires proxy assessment by a parent, of cognitive, emotional and behaviour variables and both direct and indirect endocrine measures. For children from four years of age direct cognitive assessment is also recommended as 'core'. The 'plus' components enable the addition of assessments which can be selected by individual countries and/or by, age-, treatment-, tumour type- and tumour location-specific trials.
Abstract.
Author URL.
Publications by year
2020
Limond J, Thomas S, Bull KS, Calaminus G, Lemiere J, Traunwieser T, van Santen HM, Weiler L, Spoudeas HA, Chevignard M, et al (2020). Quality of survival assessment in European childhood brain tumour trials, for children below the age of 5 years.
Eur J Paediatr Neurol,
25, 59-67.
Abstract:
Quality of survival assessment in European childhood brain tumour trials, for children below the age of 5 years.
The highest incidence rate of childhood brain tumours is in children below the age of five years, who are particularly vulnerable to the effects of treatments. The assessment of quality of survival (QoS) in multiple domains is essential to compare the outcomes for different tumour types and treatment regimens. The aim of this position statement is to present the domains of health and functioning to be assessed in children from birth to five years, to advance the collection of a common QoS data set in European brain tumour trials. The QoS group of the European Society of Paediatric Oncology (SIOP-E) Brain Tumour group conducted consensus discussions over a period of six years to establish domains of QoS that should be prioritised in clinical trials involving children under 5 years. The domains of health and functioning that were agreed to affect QoS included: medical outcomes (e.g. vision, hearing, mobility, endocrine), emotion, behaviour, adaptive behaviour, and cognitive functioning. As for children aged five years and older, a 'core plus' approach is suggested in which core assessments are recommended for all clinical trials. The core component for children from birth to three years includes indirect assessment which, in this age-group, requires proxy assessment by a parent, of cognitive, emotional and behaviour variables and both direct and indirect endocrine measures. For children from four years of age direct cognitive assessment is also recommended as 'core'. The 'plus' components enable the addition of assessments which can be selected by individual countries and/or by, age-, treatment-, tumour type- and tumour location-specific trials.
Abstract.
Author URL.
Jenny_Limond Details from cache as at 2021-09-26 01:26:01
Refresh publications
